ArticleScientific reports2025
Pan-cancer analysis of UGGT1 in human tumors and experimental validation in breast cancer.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Transcription factor BRCA1 is associated with BMPR1B transcriptional activity in sheep ovarian granulosa cells.Frontiers in veterinary science · 2025Article
Corrections and comments
- Erratum issued
Authors and funding
4 authors.
Funding
Abstract
UDP-glucose: glycoprotein glucosyltransferase 1 (UGGT1), a key component of the endoplasmic reticulum quality control (ERQC) system, has established roles in metabolic/infectious diseases, but its oncogenic potential remains unclear. UGGT1's expression, genetic alterations, methylation patterns, immune function and interacting genes were evaluated through different bioinformatics databases, and the roles of UGGT1 in breast cancer were validated by in vitro experiments. UGGT1 was significantly overexpressed in most cancers, correlating with advanced stage and poor survival. Variations in its promoter methylation and mutation patterns across cancers were associated with patient outcomes. UGGT1 status (expression/mutation) was significantly associated with immune cell infiltration in the tumor microenvironment. Functional enrichment linked UGGT1 co-expressed genes to cell cycle and nucleic acid metabolism. Critically, UGGT1 knockdown inhibited breast cancer cell proliferation/migration in vitro and downregulated key ER stress sensors (IRE1α, ATF6, PERK). This study establishes UGGT1 as a significant pan-cancer prognostic biomarker and reveals its role in tumor progression, highlighting its potential as a therapeutic target.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.